Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7805 News 


«12...1819202122232425262728...156157»
  • ||||||||||  Enrollment change, Trial termination:  T1 Diabetes Hypoglycemia Prevention Pilot (clinicaltrials.gov) -  Mar 3, 2017   
    P=N/A,  N=4, Terminated, 
    N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Primary Investigator no longer with institution N=30 --> 4 | Recruiting --> Terminated; Insufficient Resources
  • ||||||||||  Enrollment closed, Phase classification:  Comparison of Treatments Following Total Knee Replacement (clinicaltrials.gov) -  Mar 1, 2017   
    P=N/A,  N=240, Active, not recruiting, 
    Recruiting --> Completed | N=250 --> 185 Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A
  • ||||||||||  teriflunomide / Generic mfg.
    Trial primary completion date:  Teriflunomide Male Transmission Study (clinicaltrials.gov) -  Feb 28, 2017   
    P=N/A,  N=40, Recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A Trial primary completion date: Oct 2016 --> Oct 2017
  • ||||||||||  evobrutinib (M2951) / EMD Serono
    Enrollment closed, Trial primary completion date:  MS200527-0081: Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) -  Feb 28, 2017   
    P2a,  N=65, Active, not recruiting, 
    Trial primary completion date: Oct 2016 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Apr 2017
  • ||||||||||  Nucala (mepolizumab) / GSK
    Trial completion:  Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) -  Feb 28, 2017   
    P2,  N=32, Completed, 
    N=95 --> 130 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Phase classification, Enrollment change:  EDIA: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity (clinicaltrials.gov) -  Feb 27, 2017   
    P=N/A,  N=87, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | N=120 --> 87
  • ||||||||||  Enrollment status, Trial initiation date, Glucose variability:  Glucose Variability in Patients With Type 1 Diabetes With a Sucrose-added Diet (clinicaltrials.gov) -  Feb 27, 2017   
    P=N/A,  N=30, Recruiting, 
    Active, not recruiting --> Completed | Phase classification: P1 --> PN/A | N=120 --> 87 Enrolling by invitation --> Recruiting | Initiation date: May 2016 --> Feb 2017
  • ||||||||||  Trial primary completion date:  Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients (clinicaltrials.gov) -  Feb 24, 2017   
    P2,  N=20, Recruiting, 
    Enrolling by invitation --> Recruiting | Initiation date: May 2016 --> Feb 2017 Trial primary completion date: Dec 2016 --> Mar 2017
  • ||||||||||  Trial primary completion date:  TMP001 in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) -  Feb 23, 2017   
    P2a,  N=55, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Phase classification:  FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=50, Completed, 
    Phase classification: P1 --> P=N/A Phase classification: P1 --> P=N/A
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Trial primary completion date:  A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=1000, Active, not recruiting, 
    Phase classification: P1 --> P=N/A Trial primary completion date: Aug 2017 --> Apr 2017
  • ||||||||||  Trial primary completion date:  CERT-MS: Cognitive and Emotion Regulation Training in MS (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=60, Recruiting, 
    Trial primary completion date: Aug 2017 --> Apr 2017 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    New P1/2 trial, Monotherapy:  A Longitudinal Study of ACTEMRA (clinicaltrials.gov) -  Feb 23, 2017   
    P1/2,  N=10, Active, not recruiting, 
  • ||||||||||  Enrollment open, Enrollment change, Trial primary completion date:  GOCol: Graves' Orbitopathy and Hypercholesterolemia (clinicaltrials.gov) -  Feb 20, 2017   
    P=N/A,  N=200, Recruiting, 
    Active, not recruiting --> Completed Completed --> Recruiting | N=100 --> 200 | Trial primary completion date: Jan 2017 --> May 2017
  • ||||||||||  Trial primary completion date:  GOCol: Graves' Orbitopathy and Hypercholesterolemia (clinicaltrials.gov) -  Feb 16, 2017   
    P=N/A,  N=100, Completed, 
    Initiation date: Feb 2017 --> Jul 2017 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Jun 2016 --> Jan 2017
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  RhumatEx: Exercise Training in Patients With Rheumatoid Arthritis and Cryotherapy (clinicaltrials.gov) -  Feb 15, 2017   
    P=N/A,  N=8, Terminated, 
    N=15 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Jan 2017 N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Dec 2016
  • ||||||||||  Gvoke HypoPen (glucagon auto-injectable rescue pen) / Xeris Biopharma
    Enrollment open, Trial initiation date, Trial primary completion date:  Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics (clinicaltrials.gov) -  Feb 14, 2017   
    P3,  N=100, Recruiting, 
    Trial primary completion date: Nov 2016 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Feb 2017 | Trial primary completion date: Jul 2016 --> Aug 2017
  • ||||||||||  danazol oral / Generic mfg.
    Trial initiation date, Trial primary completion date:  The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia (clinicaltrials.gov) -  Feb 14, 2017   
    P2,  N=95, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Feb 2017 | Trial primary completion date: Jul 2016 --> Aug 2017 Initiation date: Jun 2011 --> Jun 2012 | Trial primary completion date: Jun 2013 --> Jul 2016
  • ||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
    Phase classification, Review, Enrollment change, Trial termination, Trial primary completion date, Compliance:  Go-Compl-Ar: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab (clinicaltrials.gov) -  Feb 13, 2017   
    P=N/A,  N=37, Terminated, 
    Initiation date: Jun 2011 --> Jun 2012 | Trial primary completion date: Jun 2013 --> Jul 2016 Phase classification: P4 --> P=N/A | N=113 --> 37 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Nov 2016; Insufficient enrollment (Terminated due to lack of patient recruitment)
  • ||||||||||  Phase classification, Trial primary completion date:  CGM-Teens: Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control (clinicaltrials.gov) -  Feb 11, 2017   
    P=N/A,  N=121, Completed, 
    Phase classification: P4 --> P=N/A | N=113 --> 37 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Nov 2016; Insufficient enrollment (Terminated due to lack of patient recruitment) Phase classification: P3 --> P=N/A | Trial primary completion date: Nov 2015 --> Feb 2017
  • ||||||||||  Benlysta (belimumab) / GSK
    Trial completion, Combination therapy:  BREVAS: Belimumab in Remission of VASculitis (clinicaltrials.gov) -  Feb 11, 2017   
    P3,  N=116, Completed, 
    Phase classification: P3 --> P=N/A | Trial primary completion date: Nov 2015 --> Feb 2017 Active, not recruiting --> Completed
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Trial completion, Phase classification, Enrollment change:  Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) -  Feb 11, 2017   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=10 --> 30